Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket reported Q2 2026 net income of $123.2 million, or $1.08 per diluted share, driven by the $180 million sale of a Priority Review Voucher. The transaction boosted cash reserves to $283.7 million, extending the company’s projected runway into the second quarter of 2028 and funding the advancement of its cardiovascular pipeline.
Key figures
- Eps
- 1.08
- Cash runway
- Q2 2028
- Ga expenses millions
- 17.4
- Cash balance millions
- 283.7
- Rnd expenses millions
- 29.5
- Prv proceeds gross millions
- 180
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.